Metabolic vulnerability in melanoma: a ME2 (me too) story
- PMID: 25666673
- PMCID: PMC4689190
- DOI: 10.1038/jid.2014.449
Metabolic vulnerability in melanoma: a ME2 (me too) story
Abstract
Metabolic reprograming is a hallmark of cancer and might represent an Achilles' heel in cancer cells. The study by Chang et al. in this issue highlights a critical role of mitochondrial malic enzyme 2 (ME2) in melanoma progression. Targeting ME2 could be an effective approach to inhibit melanoma cell proliferation and tumor growth.
Comment on
-
Human mitochondrial NAD(P)(+)-dependent malic enzyme participates in cutaneous melanoma progression and invasion.J Invest Dermatol. 2015 Mar;135(3):807-815. doi: 10.1038/jid.2014.385. Epub 2014 Sep 9. J Invest Dermatol. 2015. PMID: 25202825
References
-
- Bhandaru M, Martinka M, Li G, et al. Loss of AMPK|[alpha]|1 Expression Is Associated with Poor Survival in Melanoma Patients. Journal of Investigative Dermatology. 2014;134:1763–6. - PubMed
-
- Chang G-G, Tong L. Structure and function of malic enzymes, a new class of oxidative decarboxylases. Biochemistry. 2003;42:12721–33. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
